gotop
GNTbm-CC-01 GNTbm-CC-01
Epigenetic Immunomodulator-02 Epigenetic Immunomodulator-02
Epigenetic Immunomodulator-03 Epigenetic Immunomodulator-03
  • News+
    GNT Biotech & Medicals Co., Ltd. (GNTbm, TPEx Emerging: 7427) announced that it has awarded exclusive sales and marketing rights in Taiwan of anticancer drug Chidamide to pharmaceutical distribution company Taiwan Specialty Pharma Corp. (TSPC)
    2018-06-21
  • Immuno-Oncology therapy+
    GNTbm has focused on immuno-oncology in recent years. By exploring the dynamic and complex tumor microenvironment, GNTbm has developed the optimal anti-cancer regimen with synergistic effect of combination of both immune checkpoint inhibitor and immune modulator with novel mechanism. Immunotherapy is a novel anti-cancer therapy, which will restart the body’s natural anti-tumor immune response for efficient killing of cancer cells for such a long time, so that there is a chance to make cancer curable or become a controllable chronic disease.
  • Chidamide+
    Chidamide belongs to a new generation of epigenetic regulators and is a highly regarded new type of targeted cancer therapy that is mainly used for the treatment of solid tumors, lymphomas, and other hematopoietic tumors. Furthermore, its epigenetic regulation is a very promising mechanism that can be combined with endocrine drugs to reverse the drug resistance caused by the long-term use of endocrine inhibitors.
  • Epigenetic Immunomodulators+
    Epigenetic immunomodulator is a very important new drug for the treatment of cancers caused by  epigenetic regulatory loss of control and for use in tumor immunotherapy. It is also an important therapeutic drug to control tumor microenvironment to improve the immune response rate of tumor. It is a core new chemical entity for new drug developed by GNTbm.